Treatment of PDAC cells with recently developed inhibitors that target specific oncogenic KRAS mutants, that is, Sotorasib, Adagrasib, and MRTX1133, or block different components of the ERK1/2 or PI3K pathways (4, 5, 6), cause the cells to lose their aggressive phenotypes, underscoring the importance of RAS signaling in cancer progression (7, 8, 9). This evidence concerns the gene KRAS and cancer.